Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Stem Cell Research

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    August 2019
  1. XIAO Z, Acuna-Villaorduna A, Mantzaris I
    Brachial plexopathy following autologous hematopoietic stem cell transplant: an unrecognized complication of autologous transplantation.
    Leuk Lymphoma. 2019 Aug 20:1-3. doi: 10.1080/10428194.2019.1654094.
    PubMed     Text format    


  2. BLOCKA J, Hielscher T, Mueller-Tidow C, Goldschmidt H, et al
    Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.
    Leuk Lymphoma. 2019 Aug 19:1-10. doi: 10.1080/10428194.2019.1646905.
    PubMed     Text format     Abstract available


  3. MCILROY G, Nikolousis E, Abou-Zeid N, Shankara P, et al
    Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 11:1-4. doi: 10.1080/10428194.2019.1650177.
    PubMed     Text format    


  4. WONG E, Davis J, Koldej R, Szer J, et al
    Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 7:1-4. doi: 10.1080/10428194.2019.1648803.
    PubMed     Text format    


    July 2019
  5. KNORR DA, Goldberg AD, Stein EM, Tallman MS, et al
    Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
    Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167.
    PubMed     Text format     Abstract available


  6. YAMAGUCHI J, Chinen Y, Takimoto-Shimomura T, Nagata H, et al
    Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jul 18:1-8. doi: 10.1080/10428194.2019.1636982.
    PubMed     Text format     Abstract available


  7. STRUNZ PP, Schmalzing M, Heidemeier A, Rasche L, et al
    Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.
    Leuk Lymphoma. 2019 Jul 18:1-4. doi: 10.1080/10428194.2019.1636981.
    PubMed     Text format    


  8. HARADA K, Tachibana T, Ohashi K, Ozawa Y, et al
    The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Jul 10:1-8. doi: 10.1080/10428194.2019.1636986.
    PubMed     Text format     Abstract available


    June 2019
  9. OKAMURA-SHIKI I, Moriguchi M, Uehara T, Fukaya M, et al
    Levothyroxine tablet (Thyradin-S)-induced autoimmune-like hepatitis following post-transplant Hashimoto's thyroiditis in a patient after allogenic bone marrow transplantation.
    Leuk Lymphoma. 2019 Jun 17:1-3. doi: 10.1080/10428194.2018.1563695.
    PubMed     Text format    


    May 2019
  10. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.
    PubMed     Text format    


  11. HORGAN C, Elmoamly S, McIlroy G, Davies D, et al
    Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
    Leuk Lymphoma. 2019 May 13:1-3. doi: 10.1080/10428194.2019.1607323.
    PubMed     Text format    


    April 2019
  12. GARCIAZ S, Loschi M, De Masson A, Biard L, et al
    Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112.
    PubMed     Text format    


  13. XU M, Liu H, Liu Y, Ma X, et al
    Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-10. doi: 10.1080/10428194.2019.1597270.
    PubMed     Text format     Abstract available


  14. BEYAR-KATZ O, Lavi N, Ringelstein-Harlev S, Henig I, et al
    Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594214.
    PubMed     Text format     Abstract available


  15. SHALLIS RM, Gleeson S, Azar M, Malinis M, et al
    Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.
    Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1594221.
    PubMed     Text format    


    March 2019
  16. CHO SK, McCombs J, Punwani N, Lam J, et al
    Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
    Leuk Lymphoma. 2019 Mar 8:1-7. doi: 10.1080/10428194.2019.1581932.
    PubMed     Text format     Abstract available


  17. DOSANI T, Covut F, Pinto R, Kim BG, et al
    Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
    Leuk Lymphoma. 2019 Mar 7:1-8. doi: 10.1080/10428194.2019.1573367.
    PubMed     Text format     Abstract available


    February 2019
  18. HORVATH N, Spencer A, Kenealy M, Joshua D, et al
    Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
    Leuk Lymphoma. 2019 Feb 19:1-12. doi: 10.1080/10428194.2019.1579322.
    PubMed     Text format     Abstract available


  19. YUCEBAY F, Matthews C, Puto M, Li J, et al
    Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Leuk Lymphoma. 2019 Feb 15:1-7. doi: 10.1080/10428194.2019.1573996.
    PubMed     Text format     Abstract available


  20. OKA S, Ono K, Nohgawa M
    Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Feb 8:1-3. doi: 10.1080/10428194.2018.1537489.
    PubMed     Text format    


    January 2019
  21. SALLES GA, Pettengell R, Cordoba R, Dlugosz-Danecka M, et al
    Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
    Leuk Lymphoma. 2019 Jan 31:1-16. doi: 10.1080/10428194.2018.1564828.
    PubMed     Text format     Abstract available


  22. CHRISTEN D, Sohlbach K, Metzelder SK, Wollmer E, et al
    Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation.
    Leuk Lymphoma. 2019 Jan 15:1-6. doi: 10.1080/10428194.2018.1553303.
    PubMed     Text format     Abstract available


  23. KREFT A, Neumann H, Schindeldecker M, Wagner-Drouet EM, et al
    Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allogenic hematopoietic stem cell transplantation: a systematic approach.
    Leuk Lymphoma. 2019 Jan 11:1-10. doi: 10.1080/10428194.2018.1535118.
    PubMed     Text format     Abstract available


  24. JAIN T, Kunze KL, Khetarpal BK, McCallen MR, et al
    Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?
    Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1562183.
    PubMed     Text format     Abstract available


  25. KOSMAS C, Kranidioti E, Kosma A, Karakosta M, et al
    Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; the role of plerixafor.
    Leuk Lymphoma. 2019 Jan 8:1-4. doi: 10.1080/10428194.2018.1543879.
    PubMed     Text format    


    December 2018
  26. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Text format     Abstract available


    November 2018
  27. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Text format     Abstract available


  28. VAN MOURIK A, Grigg A
    Cerebral toxoplasmosis in a patient with prolonged CD4 lymphopenia post autologous hemopoietic stem cell transplant.
    Leuk Lymphoma. 2018 Nov 8:1-3. doi: 10.1080/10428194.2018.1485906.
    PubMed     Text format    


    October 2018
  29. TAY J, Vij R, Norkin M, Buadi F, et al
    Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.
    Leuk Lymphoma. 2018 Oct 31:1-8. doi: 10.1080/10428194.2018.1523399.
    PubMed     Text format     Abstract available


  30. SELICEAN SE, Tomuleasa C, Grewal R, Almeida-Porada G, et al
    Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1516881.
    PubMed     Text format     Abstract available


    September 2018
  31. HECKL BC, Carlet M, Vick B, Roolf C, et al
    Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509314.
    PubMed     Text format    


  32. SAHASRABUDHE K, Otto M, Hematti P, Kenkre V, et al
    TCR alphabeta+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1485905.
    PubMed     Text format     Abstract available


  33. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.
    PubMed     Text format    


  34. TANG H, Shu M, Dai B, Xu L, et al
    DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells.
    Leuk Lymphoma. 2018;59:2220-2226.
    PubMed     Text format     Abstract available


    August 2018
  35. MURNER CM, Stenner-Liewen F, Seifert B, Mueller NJ, et al
    Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.
    Leuk Lymphoma. 2018 Aug 21:1-11. doi: 10.1080/10428194.2018.1496332.
    PubMed     Text format     Abstract available


  36. DELSING MALMBERG E, Johansson Alm S, Nicklasson M, Lazarevic V, et al
    Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910.
    PubMed     Text format     Abstract available


    July 2018
  37. KAMEL AM, El-Fishawi S, Rasekh EO, Radwan ER, et al
    Variability of contribution of vitamin D receptor gene polymorphisms to outcome of HLA-matched sibling allogeneic bone marrow transplantation.
    Leuk Lymphoma. 2018 Jul 4:1-10. doi: 10.1080/10428194.2018.1459608.
    PubMed     Text format     Abstract available


  38. ADRIANZEN HERRERA D, Ayyappan S, Jasra S, Kornblum N, et al
    Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series.
    Leuk Lymphoma. 2018 Jul 3:1-7. doi: 10.1080/10428194.2018.1474523.
    PubMed     Text format     Abstract available


  39. ROMERO S, Montoro J, Guinot M, Almenar L, et al
    Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1474462.
    PubMed     Text format     Abstract available


  40. CUMMINS KD, Gill S
    Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Leuk Lymphoma. 2018;59:1539-1553.
    PubMed     Text format     Abstract available


    June 2018
  41. PERMPALUNG N, Mahoney MV, McCoy C, Atsawarungruangkit A, et al
    Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab.
    Leuk Lymphoma. 2018 Jun 27:1-7. doi: 10.1080/10428194.2018.1468896.
    PubMed     Text format     Abstract available


  42. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed     Text format    


    May 2018
  43. REICH-SLOTKY R, Makhani SS, Vasovic LV, Pearse RN, et al
    Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.
    Leuk Lymphoma. 2018 May 23:1-7. doi: 10.1080/10428194.2018.1455975.
    PubMed     Text format     Abstract available


  44. ALDERUCCIO JP, Mackrides N, Chapman JR, Vega F, et al
    Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.
    Leuk Lymphoma. 2018 May 10:1-4. doi: 10.1080/10428194.2018.1461862.
    PubMed     Text format    


  45. MORI Y, Yoshimoto G, Yuda JI, Hayashi M, et al
    Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 May 9:1-3. doi: 10.1080/10428194.2018.1466295.
    PubMed     Text format    


  46. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Text format     Abstract available


    April 2018
  47. KOBULNICKY DJ, Sabo RT, Sharma S, Shubar Ali AS, et al
    The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-9. doi: 10.1080/10428194.2018.1452216.
    PubMed     Text format     Abstract available


  48. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


  49. KJAER L, Holmstrom MO, Cordua S, Andersen MH, et al
    Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.
    Leuk Lymphoma. 2018;59:973-977.
    PubMed     Text format    


    March 2018
  50. ANDREINI A, Zampieri N, Costantini C, Malerba G, et al
    Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience.
    Leuk Lymphoma. 2018 Mar 21:1-4. doi: 10.1080/10428194.2018.1443338.
    PubMed     Text format    


  51. POLVERELLI N, Malagola M, Turra A, Skert C, et al
    Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.
    Leuk Lymphoma. 2018 Mar 12:1-6. doi: 10.1080/10428194.2018.1439584.
    PubMed     Text format    


    February 2018
  52. ICHII M, Oritani K, Murase M, Komatsu K, et al
    Molecular targeting of inosine-5'-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway.
    Leuk Lymphoma. 2018;59:448-459.
    PubMed     Text format     Abstract available


    January 2018
  53. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.
    PubMed     Text format    


  54. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Text format     Abstract available


  55. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  56. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed     Text format    


  57. CHEN A, Chao K, Rodriguez L, Munday W, et al
    Toxic epidermal necrolysis versus cutaneous Graft-Versus-Host Disease in a hematopoietic stem cell transplant recipient: the role of elafin.
    Leuk Lymphoma. 2018 Jan 11:1-3. doi: 10.1080/10428194.2017.1422867.
    PubMed     Text format    


    December 2017
  58. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  59. TANDRA A, Covut F, Cooper B, Creger R, et al
    Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1390234.
    PubMed     Text format     Abstract available


    November 2017
  60. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Text format     Abstract available


  61. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed     Text format    


    October 2017
  62. STEVENS H, Raj K, Ashby M, Grigg A, et al
    Allogeneic stem cell transplantation as a risk factor for recurrent melanoma.
    Leuk Lymphoma. 2017 Oct 31:1-3. doi: 10.1080/10428194.2017.1393670.
    PubMed     Text format    


  63. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.
    PubMed     Text format    


  64. PATEL P, Oh AL, Koshy M, Sweiss K, et al
    A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
    Leuk Lymphoma. 2017 Oct 25:1-6. doi: 10.1080/10428194.2017.1390231.
    PubMed     Text format     Abstract available


  65. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Text format     Abstract available


  66. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  67. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  68. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


  69. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    September 2017
  70. ZINTER MS, Melton A, Sabnis AJ, Dvorak CC, et al
    Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
    Leuk Lymphoma. 2017 Sep 28:1-4. doi: 10.1080/10428194.2017.1382697.
    PubMed     Text format    


  71. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Text format     Abstract available


    June 2017
  72. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


    May 2017
  73. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


    January 2017
  74. PETERSON LF, Lo MC, Liu Y, Gianolla D, et al
    Induction of p53 suppresses chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-14. doi: 10.1080/10428194.2016.1272682.
    PubMed     Text format     Abstract available


  75. ISHII H, Konuma T, Kato S, Oiwa-Monna M, et al
    Impact of hematogones on the long-term outcomes of single-unit cord blood transplantation for adult patients.
    Leuk Lymphoma. 2017;58:118-126.
    PubMed     Text format     Abstract available


    March 2016
  76. BELTON A, Xian L, Huso T, Koo M, et al
    STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    January 2016
  77. VALTOLA J, Varmavuo V, Ropponen A, Selander T, et al
    Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  78. SANFORD D, Garcia-Manero G, Jorgensen J, Konoplev S, et al
    CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    December 2015
  79. GARG S, Shanmukhaiah C, Ghosh K, Madkaikar M, et al
    Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: